02.08.01. Investigación y comunicación científica

Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH)

2026-05-13T11:04:53Z

Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH) Valero-García, Silvia; González-Haba, Eva; Queralt-Gorgas, María; Alonso-Herreros, José-María; Cercos-Lleti, Ana-Cristina; Poveda-Andrés, José-Luis; Calleia-Hernández, Miguel-Ángel; Delgado-Sánchez, Olga OBJECTIVE: To establish a series of recommendations based on available evidence for monitoring surface contamination in the areas devoted to compounding hazardous drugs in pharmacy departments. METHOD: Based on a literature search in the Medline and Embase databases (search period: January 2009 to July 2019), as well as on a review of standards and recommendations issued by different healthcare organizations, a committee of experts from the Spanish Society of Hospital Pharmacists defined a series of safe practices for handling hazardous drugs and monitoring compounding work surfaces. Recommendation decisions were adopted by consensus among the members of the expert group, considering the recommendations reviewed, the monitoring situation in Spanish hospital departments, and the associated costs. RESULTS: Ten recommendations were formulated, structured into eight sections. They include aspects related to the drugs to be monitored; the areas to be monitored; when samples should be taken; risk determination and preparation of a sampling protocol; analytical techniques; contamination thresholds; and design of an action plan based on the sampling and decontamination results obtained. CONCLUSIONS: Surface monitoring allows hazardous drugs detection and evaluation of the effectiveness of current protocols for the safe handling of such drugs in hospital pharmacy departments. The evaluation should include an analysis of the efficacy of engineering controls, work practices and cleaning and decontamination processes.

The importance of quality control in raw materials used in pharmaceutical formulations

2026-05-13T11:04:52Z

The importance of quality control in raw materials used in pharmaceutical formulations Ramos-Martínez, Beatriz; Alonso-Herreros, José-María; Martin-de-Rosales-Cabrera, Ana-María

Nationwide Implementation of Double Reflex Testing for Hepatitis Delta in Spain: Results From the Retrospective Phase of the Spain-DDR Study

2026-05-13T11:02:52Z

Nationwide Implementation of Double Reflex Testing for Hepatitis Delta in Spain: Results From the Retrospective Phase of the Spain-DDR Study Alberola, Ana; De-Salazar, Adolfo; Fuentes, Ana; Carracedo, Raquel; Illescas-lopez, Marta; Rodríguez-Baños, María-del-Carmen; Freyre, Carolina; Becerril, Berta; Viciana, Isabel; López-rodriguez, Inmaculada; Montiel, Natalia; Domínguez-Castaño, Ana-María; Luzón-García, María-Pilar; Ramírez-Arellano, Encarnación; Liébana-martos, Carmen; Franco-Álvarez-de-Luna, Francisco; Lozano, María-del-Carmen; Palop, Begona; Sampedro, Antonio; Pérez, Ana-Belén; Algarate, Sonia; Rojo-Alba, Susana; Fraile, Pablo; Ocete, Dolores; Alcaraz, María-Jesús; Rodríguez, Juan-Carlos; Hernández-Felices, Francisco-Javier; Martínez, Olalla; Domínguez, Victoria; Orta, Nieves; Gómez, Dolores; Cortell, Carmen; Camacho, Jorge; Sabater, Susana; Iglesias-Sánchez, Luis-Ángel; Martin, Yasmina; Vallejo, Aldara; Molina, Lourdes; Aroca, María; Castro, Beatriz; Lara, Magdalena; Pena, María-José; Rodríguez-fernández, Ana; González-Praetorius, Alejandro; Blas, José-Joaquín; Beteta, Alicia; Gómez, Cesar; Rodríguez, María-José; Illescas, Soledad; Abreu, Melanie; García-Díez, Julio; Beltran, Inocencio; Sandoval-Torrientes, Marta; Sáez, Ruth; Martín, Teresa; Tajada-Alegre, Pilar; Lorenzo, Belén; García-Valero, María-Teresa; Jiménez-Sansegundo, Isabel; García-de-Cruz, Susana; Garcinuno, Sonsoles; Saiz, Miguel-Ángel; Muñoz, Santiago; Fernández, Isabel; Lorenzo-Juanes, Helena-Miriam; Vidal-Acuña, María-Reyes; Moldes, Luz-María; Calvo, Noelia; Trigo, Matilde; Gude, María-José; Ordonez, Patricia; Cortizo, Sandra; Blasco, Miriam; Sigcha, Mayra; Falcés, Iker; Galan, Juan-Carlos; Arribi, Ana; Alonso, Roberto; Iborra-Bendicho, María-Asunción; del-Amor-Espín, María-Jesús; Cascales-Alcolea, Eva; Pérez-Pardo, Cayetano; Fernández, Pablo; Navarro-Martínez, María-Dolores; Núñez-Trigueros, María-Luz; Galán-Ros, Jorge; Gil-gallardo, Luis-Javier; Miqueleiz, Ana; Reina, Gabriel; Elorduy, Luis; Macho, Mikele; Gómez, Carmen; Liendo, Paloma; Salicio, Yolanda; Aguilera, Antonio; García, Federico BACKGROUND: Hepatitis delta virus accelerates liver disease progression in chronic hepatitis B, yet remains underdiagnosed. Guidelines recommend double reflex diagnostic testing with antibody testing followed by viral load testing, but uptake remains inconsistent. AIMS: To evaluate double reflex diagnostic implementation in Spain during the retrospective phase of the Spain Double Reflex Diagnostic study. METHODS: Nationwide, multicenter retrospective analysis of individuals positive for hepatitis B surface antigen (2022-2024) from 80 centers. Laboratory data included hepatitis B surface antigen, hepatitis delta virus antibody and hepatitis delta virus viral load. Uptake rates, hepatitis delta virus antibody positivity, viral load confirmation and viral load-confirmed prevalence were calculated with 95% confidence intervals. RESULTS: Among 65,763 individuals positive for hepatitis B surface antigen, hepatitis delta virus antibody testing uptake increased from 55.1% (54.4-55.8) in 2022 (n = 18,986) to 72.5% (71.9-73.1) in 2023 (n = 22,463) and 85.8% (85.1-86.4) in 2024 (n = 24,314; p < 0.0001). Antibody positivity remained stable (5.6%, 4.9%, 5.3%). Viral load confirmation among antibody-positive patients improved from 72.6% in 2022 to 90.8% in 2023 and 91.0% in 2024. Viral load-confirmed prevalence among antibody-positive individuals was 40.3% in 2022, 31.6% in 2023, and 30.1% in 2024. Regional heterogeneity was marked, with several autonomous communities achieving near-universal uptake (> 95%). CONCLUSION: Between 2022 and 2024, double reflex diagnostic implementation expanded rapidly, demonstrating national feasibility and describing hepatitis D virus seroprevalence. However, regional inequities persist. Sustained uptake will require standardised reflex protocols, harmonization of viral load assays and continuous training to reduce underdiagnosis and improve care of coinfected patients.

Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

2026-05-12T08:34:36Z

Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period Polo-y-La-Borda, Jessica; Castañeda, Santos; Heras-Recuero, Elena; Sánchez-Alonso, Fernando; Plaza, Zulema; García-Gómez, Carmen; Ferraz-Amaro, Ivan; Sánchez-Costa, Jesús-Tomás; Sánchez-González, Olga-Carmen; Turrión-Nieves, Ana-Isabel; Pérez-Alcalá, Ana; Pérez-García, Carolina; González-Juanatey, Carlos; Llorca, Javier; González-Gay, Miguel Objective: To assess the predictive value of four cardiovascular (CV) risk algorithms for identifying high-risk psoriatic arthritis (PsA) patients. Methods: Evaluation of patients with PsA enrolled in the Spanish prospective project CARdiovascular in RheuMAtology. Baseline data of 669 PsA patients with no history of CV events at the baseline visit, who were followed in rheumatology outpatient clinics at tertiary centres for 7.5 years, were retrospectively analysed to test the performance of the Systematic Coronary Risk Assessment (SCORE), the modified version (mSCORE) European Alliance of Rheumatology Associations (EULAR) 2015/2016, the SCORE2 algorithm (the updated and improved version of SCORE) and the QRESEARCH risk estimator version 3 (QRISK3). Results: Over 4790 years of follow-up, there were 34 CV events, resulting in a linearised rate of 7.10 per 1000 person-years (95% CI 4.92 to 9.92). The four CV risk scales showed strong correlations and all showed significant associations with CV events (p<0.001). SCORE, mSCORE EULAR 2015/2016 and QRISK3 effectively differentiated between low and high CV risk patients, although the cumulative rate of CV events observed over 7.5 years was lower than expected based on the frequency predicted by these risk scales. Additionally, model improvement was observed when combining QRISK3 with any other scale, particularly the combination of QRISK3 and SCORE2, which yielded the lowest Akaike information criterion (411.15) and Bayesian information criterion (420.10), making it the best predictive model. Conclusions: Risk chart algorithms are very useful for discriminating PsA at low and high CV risk. An integrated model featuring QRISK3 and SCORE2 yielded the optimal synergy of QRISK3's discrimination ability and SCORE2's calibration accuracy.